LMAT

Insider Trades

Name	Value	Action	Price	Current Price
LeMaitre George WDirector, Officer: Chairman And CEO $3.0M27.9k shares SellMay 8, 2026 $108.69 --
Kamke Trent GSenior V. P., Operations $313k2.9k shares SellMay 8, 2026 $107.00 --
LeMaitre George WDirector, Officer: Chairman And CEO $2.0M18.6k shares SellMay 7, 2026 $107.64 --
Ross Bridget ADirector $560k5k shares SellMay 7, 2026 $111.10 --
Jasinski Lawrence JDirector $434k3.9k shares SellMay 7, 2026 $110.00 --

News

seekingalpha.comWe Have A Valuation Problem - May Dividend Income Reportseekingalpha.comJun 18

zacks.comCasey's & 3 More Stocks With Strong Interest Coverage to Buy Nowzacks.comMay 26

zacks.comLeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Whyzacks.comMay 25

globenewswire.comLeMaitre to Participate at Upcoming Investor Conferences in Juneglobenewswire.comMay 20

zacks.comDown 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaroundzacks.comMay 13

Trade LMAT

About LeMaitre Vascular, Inc.

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.

CEO: George W. LeMaitre
IPO Date: Oct 19, 2006

Market Data

Open: $92.68
High: $94.35
Low: $92.33
Volume: 720.8K
Avg Volume: 267.7K
52W High: $118.01
52W Low: $79.01

Valuation

Market Cap: $2.1B
Enterprise Value: $2.3B
Dividend Yield: 90.0%

Financials

Free Cash Flow: $74M
Revenue: $250M
Net Income: $58M
Cash: $28M
Debt: $186M

Events

EarningsAug 4

EPS est. 0.81